Engineering therapeutic proteins
Engineering therapeutic proteins
复制标题
DOI：
10.1016/s0959-440x(00)00108-1
复制
发表时间：
2000-08-01
影响因子：
6.8
通讯作者：
Glover, DR
中科院分区：
文献类型：
--
作者：
McCafferty, J;Glover, DR
许多来自生物技术的早期候选药物由于亲和力/特异性低、半衰期短或免疫原性低而未能通过临床试验。蛋白质工程技术已被应用于绕过阻碍这些早期试验的一些问题，从而从一系列工程抗体和其他蛋白质中获得临床益处。
Many early drug candidates derived from biotechnology failed in clinical trials because of their low affinity/specificity short half-lives or immunogenicity. Protein engineering techniques have been applied to circumvent some of the problems that hindered these earlier trials, resulting in clinical benefits from a range of engineered antibodies and other proteins.